Skip to main content
Site Search
Close Search

RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Digital PCR

Digital is the new absolute

Who we are

Learn about who we are and what we do to make improvements in life possible.

Join the QIAGEN team

Latest information on COVID-19

News, testing solutions and stories covering global efforts in the fight against COVID-19.

Our stories

Explore our digital magazine full of customer stories and videos on scientific breakthroughs and healthcare advances.

    Market Strategy

    Read our equity story, financial disclosures and how we create shareholder value.

      Latest News

      Read up on our latest press releases or peruse our various media archives.

      Contact Us

      Thank you for choosing QIAGEN. If you have questions about QIAGEN, our products or your order, this page should help you find the answers and contacts you need.
      Overview

      Directors Dealings

      Home  >  Investor Relations  >  Financial Reports & SEC Filings  >  Directors Dealings

      QIAGEN publishes information on directors' dealings as reported to the company and pursuant to regulations by the United States Securities and Exchange Commission (SEC) and the Netherlands Authority for the Financial Markets (A-FM) pursuant to Section 2a Wmz 1996 and Art. 19. EU Directive No. 596/2014. Our insider trading policy can be downloaded as PDF document here.

      Notes to the overview of recent transactions

      * Cashless Exercise

      1) According to a Rule 10b5-1 long-term Sales Plan ("Langzeitverkaufsvertrag").

      2) Lawrence A. Rosen, Stéphane Bancel, Metin Colpan, Thomas Ebeling, Toralf Haag, Ross L. Levine, Elaine R. Mardis, Lawrence A. Rosen, Elizabeth E. Tallett.

      “Net share settlement” is done when a number of shares to cover expenses related to the grant release (such as taxes and transaction costs) are withheld by the Company.

      Recent transactions

      Name and function Date and type Financial instrument Amount of shares SEC BAFin A-FM
      Roland Sackers,
      Managing Director      		 11/26/21
      Sale      		 Common Shares 40,668 PDF PDF PDF
      Roland Sackers,
      Managing Director      		 10/31/21 Common Shares received through release of Performance Stock Units ("net share settlement") 40,668 - PDF PDF
      Thierry Bernard,
      Managing Director      		 07/26/21
      Purchase      		 Common Shares 2,000 - PDF PDF
      Roland Sackers,
      Managing Director      		 07/26/21
      Purchase      		 Common Shares 2,000 - PDF PDF
      Thierry Bernard,
      Managing Director      		 06/30/21
      Grant      		 Performance Stock Units 113,683 - PDF PDF
      Roland Sackers,
      Managing Director      		 06/30/21
      Grant      		 Performance Stock Units 87,322 - PDF PDF
      Stéphane Bancel,
      Supervisory Director      		 06/29/21   Common Shares received through release of Restricted Stock Units ("net share settlement") 9,582 - PDF PDF
      Lawrence A. Rosen,
      Supervisory Director      		 05/11/21   Common Shares 5,421 PDF PDF PDF
      Roland Sackers,
      Managing Director      		 04/13/21 1)  Common Shares
      (Transaction completed as part of a long-term 10b5-1 trading plan to sell shares at a predetermined price)      		 30,000 PDF PDF PDF
      Elaine Mardis,
      Supervisory Director      		 03/17/21 Common Shares 4,909 PDF PDF PDF
      Stéphane Bancel,
      Supervisory Director      		 03/02/21 Common Shares 4,968 PDF PDF PDF
      Lawrence A. Rosen,
      Supervisory Director      		 03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,326 - PDF PDF
      Stéphane Bancel,
      Supervisory Director      		 03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,037 - PDF PDF
      Metin Colpan,
      Supervisory Director      		 03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,238 - PDF PDF
      Elaine R. Mardis,
      Supervisory Director      		 03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,008 - PDF PDF
      Elizabeth E. Tallett,
      Supervisory Director      		 03/01/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 3,326 - PDF PDF
      Thierry Bernard,
      Managing Director      		 03/01/21 Common Shares received through release of Performance Stock Units ("net share settlement") 2,477 - PDF PDF
      Roland Sackers,
      Managing Director      		 03/01/21 Common Shares received through release of Performance Stock Units ("net share settlement") 12,430 - PDF PDF
      Lawrence A. Rosen,
      Supervisory Director      		 02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 2,095 - PDF PDF
      Stéphane Bancel,
      Supervisory Director      		 02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 1,931 - PDF PDF
      Metin Colpan,
      Supervisory Director      		 02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 2,217 - PDF PDF
      Ross L. Levine,
      Supervisory Director      		 02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 1,978 - PDF PDF
      Elaine R. Mardis,
      Supervisory Director      		 02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 1,901 - PDF PDF
      Elizabeth E. Tallett,
      Supervisory Director      		 02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 2,095 - PDF PDF
      Roland Sackers,
      Managing Director      		 02/28/21 Common Shares received through release of Restricted Stock Units ("net share settlement") 6,923 - PDF PDF
      All Supervisory
      Board Directors2)      		 02/26/21 Grant Restricted Stock Units 7,482 - PDF PDF
      Roland Sackers,
      Managing Director      		 02/26/21 Common Shares received through release of Performance Stock Units ("net share settlement") 5,594 - PDF PDF
      Thierry Bernard,
      Managing Director      		 02/21/21 Common Shares received through release of Performance Stock Units ("net share settlement") 10,371 - PDF PDF
      Roland Sackers,
      Managing Director      		 02/21/21 Common Shares received through release of Performance Stock Units ("net share settlement") 21,467 - PDF PDF
      Metin Colpan,
      Supervisory Director      		 02/16/21-02/17/21 Common Shares 770,370 - PDF PDF
      Thierry Bernard,
      Managing Director      		 02/15/21 Common Shares received through release of Performance Stock Units ("net share settlement") 23,410 - PDF PDF